GigaGen uses its proprietary technology to quickly characterize every cell in complex immune systems, powering the selection of drug targets, identification of drug candidates, and preclinical assessment of efficacy. The company develops antibody therapies, including monoclonal oncology drugs and recombinant polyclonal gammaglobulin therapies, for the treatment of immune deficiency, infectious diseases, and checkpoint resistant cancers. Its technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries, enabling the creation of first-in-class recombinant polyclonal antibody therapies for the treatment of infectious diseases. GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases.